(Total Views: 269)
Posted On: 09/04/2019 7:26:53 AM
Post# of 145250
2 years ago this announcement would have jumped the price up hard. With the failure rate of NASH candidates I think investors will take a wait and see attitude. Although looking at cenicriviroc trials not only should leronlimab combat liver fat, but actually inhibit fibrosis.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)